This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Not applicable	<p><i>In vitro</i> and mouse studies showed antiangiogenic compounds had the undesirable side effect of increasing proliferation of cancer stem cells (CSCs), suggesting antiangiogenic compounds should be combined with CSC-targeting molecules. In mice with human breast cancer xenografts, the antiangiogenic small molecule Sutent sunitinib caused primary tumor regression but increased the number of CSCs, tumor hypoxia and tumor invasiveness compared with vehicle. Next steps include testing antiangiogenic compounds and CSC-targeted therapies in preclinical cancer models.</p> <p>Pfizer Inc. markets the receptor tyrosine kinase (RTK) inhibitor Sutent to treat various cancers.</p> <p>SciBX 5(11); doi:10.1038/scibx.2012.278 Published online March 15, 2012</p>	Patent and licensing status unavailable	<p>Conley, S.J. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Jan. 23, 2012; doi:10.1073/pnas.1018866109</p> <p>Contact: Max S. Wicha, University of Michigan, Ann Arbor, Mich. e-mail: mwicha@umich.edu</p>